Tredje AP fonden Acquires 13,424 Shares of Becton, Dickinson and Company $BDX

Tredje AP fonden boosted its holdings in Becton, Dickinson and Company (NYSE:BDX) by 6.8% during the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 211,720 shares of the medical instruments supplier’s stock after acquiring an additional 13,424 shares during the quarter. Tredje AP fonden’s holdings in Becton, Dickinson and Company were worth $36,469,000 at the end of the most recent reporting period.

A number of other large investors have also recently modified their holdings of the business. Bill Few Associates Inc. grew its holdings in shares of Becton, Dickinson and Company by 0.7% during the second quarter. Bill Few Associates Inc. now owns 7,906 shares of the medical instruments supplier’s stock worth $1,362,000 after purchasing an additional 55 shares in the last quarter. Gilbert & Cook Inc. lifted its position in Becton, Dickinson and Company by 2.0% during the second quarter. Gilbert & Cook Inc. now owns 2,844 shares of the medical instruments supplier’s stock valued at $490,000 after purchasing an additional 56 shares during the last quarter. Mendel Money Management grew its stake in Becton, Dickinson and Company by 2.6% in the 2nd quarter. Mendel Money Management now owns 2,254 shares of the medical instruments supplier’s stock worth $388,000 after buying an additional 58 shares in the last quarter. Stephens Inc. AR increased its holdings in shares of Becton, Dickinson and Company by 0.3% in the 1st quarter. Stephens Inc. AR now owns 18,578 shares of the medical instruments supplier’s stock worth $4,255,000 after buying an additional 59 shares during the last quarter. Finally, Plancorp LLC raised its position in shares of Becton, Dickinson and Company by 4.1% during the 1st quarter. Plancorp LLC now owns 1,499 shares of the medical instruments supplier’s stock valued at $343,000 after buying an additional 59 shares in the last quarter. Institutional investors own 86.97% of the company’s stock.

Insider Buying and Selling

In other Becton, Dickinson and Company news, Director Claire Fraser sold 917 shares of the stock in a transaction on Wednesday, September 10th. The shares were sold at an average price of $187.50, for a total transaction of $171,937.50. Following the completion of the sale, the director owned 22,226 shares of the company’s stock, valued at $4,167,375. This represents a 3.96% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In the last three months, insiders have sold 1,895 shares of company stock worth $358,995. Corporate insiders own 0.36% of the company’s stock.

Analyst Ratings Changes

A number of research analysts recently commented on the company. Royal Bank Of Canada reissued a “sector perform” rating and issued a $211.00 target price on shares of Becton, Dickinson and Company in a research note on Thursday, October 16th. Morgan Stanley upped their price objective on Becton, Dickinson and Company from $196.00 to $197.00 and gave the stock an “overweight” rating in a report on Monday, August 11th. Argus raised their price objective on Becton, Dickinson and Company from $220.00 to $230.00 in a report on Monday, September 15th. Wells Fargo & Company upped their target price on Becton, Dickinson and Company from $172.00 to $184.00 and gave the stock an “equal weight” rating in a research note on Friday, August 8th. Finally, Piper Sandler reissued a “neutral” rating and set a $200.00 price target (up from $185.00) on shares of Becton, Dickinson and Company in a research note on Friday, August 8th. Three equities research analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $205.40.

Becton, Dickinson and Company Trading Down 0.3%

Shares of BDX stock opened at $178.77 on Friday. The business has a 50-day moving average of $188.38 and a 200 day moving average of $183.04. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.10 and a quick ratio of 0.62. Becton, Dickinson and Company has a 1-year low of $163.33 and a 1-year high of $251.99. The stock has a market capitalization of $51.24 billion, a PE ratio of 32.15, a P/E/G ratio of 1.42 and a beta of 0.25.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings data on Thursday, April 14th. The medical instruments supplier reported $4.10 earnings per share for the quarter. The firm had revenue of $5.32 billion during the quarter. Becton, Dickinson and Company had a return on equity of 16.23% and a net margin of 7.51%. As a group, sell-side analysts anticipate that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.